His research interests focus on novel treatments for metastatic melanoma and he is currently the principal investigator or co-investigator on a number of therapeutic clinical trials. He is a member of several professional societies including the American Society of Clinical Oncology, Southwest Oncology Group, and Society for Melanoma Research. He has coauthored numerous scientific articles and abstracts and has presented at national meetings.
Lewis KD, Robinson WA, Millward MJ, Powell A, Price TJ, Thomson DB, Walpole ET, Haydon AMM, Creese BR, Roberts KL, Zalcberg JR, Gonzalez R: A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma. Invest New Drugs 26(4):89-94, 2008.
McCarter M, Baumgartner J, Escobar G, Richter D, Lewis K, Robinson W, Wilson C, Palmer B, Gonzalez R: Immunosuppressive Dendritic and Regulatory T Cells are Upregulated in Melanoma Patients. Ann Surg Oncol 14(10):2854-2860, 2007.
Lewis KD, Robinson WA, McCarter M, Pearlman N, O’Day SJ, Anderson C, Amatruda TT, Baron A, Zeng C, Becker M, Dollarhide S, Matijevich K, Gonzalez R. A phase II, multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma. J Clin Oncol 24(19): 3157-3163, 2006.
Lewis KD, Thompson JA, Robinson WA, Floret S, Ruvuna F, Gonzalez R. A Phase II open-label trial of Apomine (SR-45023A) in patients with refractory melanoma. Investigational New Drugs 24(1): 89-94, 2006.